The report provides a detailed analysis of the current acute respiratory distress syndrome (ARDS) marketed drugs and late-stage pipeline drugs. Inside the ARDS Market | How Tech, Awareness, Rising ...

In a single-center study, Milberg et al [86] reported no overall change in mortality rates for patients with ARDS from 1983 to 1987, a slight decline in 1988 and 1989, and a decrease to a low of ...

Objective To determine whether neuromuscular blocking agents (NMBAs) can decrease the mortality of patients with acute respiratory distress syndrome (ARDS) and improve their clinical outcomes. Design ...

The R/I ratio showed limited accuracy in predicting lung recruitability in ARDS but reliably identified low recruiters.

Sir Kenneth Branagh made a surprise video appearance as some of Northern Ireland’s unsung heroes were celebrated tonight.

There is no single test for scleroderma. It is a clinical diagnosis that requires a thorough exam and history by the doctor. The doctor will start by asking questions about symptoms and previous ...

Fast Track status enables expedited regulatory review timelines and supports the development of recombinant human plasma gelsolin (rhu-pGSN), a novel immune modulator for inflammatory diseases. Global ...

BioAegis Therapeutics Receives FDA Fast Track Designation for Lead Product, Recombinant Human Gelsolin, for the Treatment of Acute Respiratory Distress Syndrome (ARDS)Fast Track status enables ...

CNN — Actor Eric Dane is opening up about living with ALS. In his first television interview since revealing he has amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's Disease, Dane, 52, ...

CNN — Actor Eric Dane is opening up about living with ALS. In his first television interview since revealing he has amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's Disease, Dane ...

BioAegis’ lead product, rhu-pGSN, is currently being studied in a 600-patient global Phase 2 trial for patients with moderate to severe Acute Respiratory Distress Syndrome (ARDS).

BioAegis’ lead product, rhu-pGSN, is currently being studied in a 600-patient global Phase 2 trial for patients with moderate to severe Acute Respiratory Distress Syndrome (ARDS). This project has ...